Back to search results

Hyperpolarized 13C MRI for Myocardial Viability

This study is looking at a special type of MRI called Hyperpolarized 13C MRI to help doctors decide if patients with coronary artery disease (blocked heart arteries) would benefit from bypass surgery. This MRI method helps to see how well your heart muscle is working by tracking two natural chemicals, bicarbonate and lactic acid. The study will measure these chemicals in patients before and after bypass surgery, and compare them to healthy people. This research aims to find a better way to choose patients for bypass surgery, as current methods aren't always clear. You may be able to join if you are between 20 and 80 years old and have ischemic heart disease (heart disease caused by reduced blood flow).

Study design
This is an observational study involving 30 participants. It will compare heart metabolism in healthy individuals and patients with coronary artery disease.
What's involved
You would have an MRI scan at the beginning of the study. If you have bypass surgery, you would have another MRI scan 4-6 months later.
Compensation
Not stated in the trial record.
Follow-up
Participants who undergo surgery will be followed for 4-6 months after their procedure for a follow-up MRI.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06047028

Prognostic Value of Hyperpolarized 13C MRI for Clinical Myocardial Viability

Recruiting
Not specifiedAges 20–80Observational
University of Texas Southwestern Medical Center
~30 participants
Updated 2026-02-27 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Bicarbonate-to-Lactate Ratio in Healthy Control Subjects
Measured over Baseline (Day 1 of imaging)
+2 more outcomes measured

Conditions

Coronary Artery Disease
Ischemic Heart Disease (IHD)
Myocardial Viability

Explore related trials

Coronary Artery Disease

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Gaurav Sharma, PhD. · PRINCIPAL_INVESTIGATOR · University of Texas Southwestern Medical Center

Who to contact

Sarah S McNeil
[email protected]
214-645-7700
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age range: 20 to 80 years
Sex: Random allocation
Left ventricular ejection fraction (LVEF):
Preoperative patients with LVEF \< 0.35
Healthy subjects with LVEF \> 0.50
Clinical history:
Previous myocardial infarction (MI): Excluded for healthy subjects, included for preoperative patients.
Diabetes mellitus: Excluded for all participants.
Hypertension: Included for all participants
Mean blood pressure: Systolic \< 140 mm Hg and Diastolic \< 90 mm Hg for all participants
Mean heart rate: 78 beats/min for all participants
Current smoker status: Included but will be reported.
Medication use within 24 hours: Use will be reported.
Coronary artery bypass surgery history: Excluded for healthy subjects, included for preoperative patients.
Infarct type and location: Excluded for healthy subjects, included for preoperative patients with various Q-wave infarct types and locations.
Number of diseased coronary vessels: Excluded for healthy subjects, included for preoperative patients with at least one diseased vessel.
Additional medical history and clinical data: Variations in data availability are expected based on the practices of referring physicians and will be documented.

What this trial measures

  • Bicarbonate-to-Lactate Ratio in Healthy Control SubjectsBaseline (Day 1 of imaging)

    Assessment of normal segmental myocardial metabolism by measuring the ratio of hyperpolarized (HP) \[13C\]-bicarbonate to HP \[1-13C\]lactate (bic/lac ratio). This is obtained during an HP-13C MRI utilizing \[1-13C\] pyruvate to establish baseline normal values for healthy subjects.

  • Bicarbonate-to-Lactate Ratio in Preoperative CAD PatientsPreoperative imaging day

    Assessment of segmental myocardial metabolism and mechanical function in patients scheduled for coronary artery bypass surgery. The bic/lac ratio is measured using HP-13C MRI to identify abnormal cardiac metabolism and impaired oxidative function. These metabolic findings will be correlated with echocardiographic measurements of wall motion and viability studies obtained by the referring cardiologist.

  • Change in Bicarbonate-to-Lactate Ratio Post-Surgery4-6 months after surgical coronary revascularization

    Follow-up assessment of segmental myocardial metabolism to evaluate the remodeling of cardiac metabolism as a consequence of surgery. The bic/lac ratio is measured using HP-13C MRI to determine if the ratio has increased compared to the patient's preoperative baseline, indicating improved oxidative function.